Mitsubishi Chemical picks Bain as preferred bidder for pharma …
6 days ago · Japan's Mitsubishi Chemical Group has picked U.S. investment fund Bain Capital as the preferred bidder for its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma, in a deal that could value it at ...
Mitsubishi Chemical picks Bain as preferred bidder for pharma
TOKYO/HONG KONG (Reuters) -Japan's Mitsubishi Chemical Group has picked U.S. investment fund Bain Capital as the preferred bidder for its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma, in a ...
Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma - MSN
Bain Capital is in talks to acquire Mitsubishi Chemical Group’s pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a transaction that could ...
Mitsubishi Chemical picks Bain as preferred bidder for subsidiary ...
6 days ago · TOKYO (Reuters) -Mitsubishi Chemical Group picked U.S. investment fund Bain Capital as the preferred bidder for its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma, the Nikkei reported on Monday. The company is likely to sell its Tanabe Mitsubishi Pharma unit to Bain Capital for more than 500 billion yen ($3.2 billion), the report said.
Bain Capital Reportedly In Talks To Buy Mitsubishi Chemical's …
5 days ago · (RTTNews) - Investment firm Bain Capital is in talks to acquire Mitsubishi Tanabe Pharma Corp., affiliated to Japan's Mitsubishi Chemical Group (MTLHF.PK), in a potential deal, reports said citing ...
Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma
Bain Capital is in talks to acquire Mitsubishi Chemical Group’s 4188 0.06% pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a...
Blackstone, Bain to bid for Mitsubishi pharma unit in up to $3.5 …
Dec 13, 2024 · Global private equity firms Blackstone and Bain Capital are among final bidders for Mitsubishi Tanabe Pharma, a unit of Japan's Mitsubishi Chemical Group, in a deal that could value it at...
Mitsubishi Chemical picks Bain as preferred bidder for subsidiary …
The company is likely to sell its Tanabe Mitsubishi Pharma unit to Bain Capital for more than 500 billion yen ($3.2 billion), the report said. Mitsubishi Chemical was not immediately available for
Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma -- Update
5 days ago · Mitsubishi Tanabe's best-selling drugs include Radicava for amyotrophic lateral sclerosis, which competes with Biogen's Qalsody. Japanese business daily Nikkei reported earlier that Mitsubishi Chemical had given preferential negotiation rights to Bain Capital for the potential sale of the pharmaceutical unit.
Mitsubishi Chemical Eyes $3.2 Billion Deal with Bain Capital
6 days ago · For Bain Capital, the acquisition of Mitsubishi Tanabe Pharma aligns with its broader strategy of doubling investments in Japan. Bain has been aggressively pursuing opportunities in key industries across the country, including technology, healthcare, and retail. The potential deal, valued at over $3.2 billion, would allow Bain to tap into ...
- Some results have been removed